Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-06-14
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited and gene-based medicines, led by approved hemoglobinopathy therapy CASGEVY and a pipeline in autoimmune, oncology, cardiometabolic, rare disease and siRNA programs.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From scientific proof to franchise proof
An approved first product and unusually strong balance sheet give it time to prove a second franchise. The upside case needs validation beyond hemoglobinopathies, not just steady CASGEVY launch math.

Analysis

Thesis
CRISPR Therapeutics already cleared the hardest credibility hurdle with CASGEVY; if it can turn that proof into steadier commercial economics and validate one owned follow-on franchise by 2031, the stock can rerate from cash-plus-optionality to a real multi-asset gene-editing platform.
Last Economy Alignment
AI should improve target selection, design, and portfolio triage, but value still clears through regulated biology, manufacturing, and payer trust. CRISPR benefits from cheaper cognition without being easily commoditized by it.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.8x (from 5 most recent analyses)
Reasoning
The rerating case is not that every program works. It is that CASGEVY becomes a steadier economic base and one owned program proves repeatable human efficacy, giving investors a second real franchise to underwrite. That is enough for strong returns from today's level, but treatment logistics, regulatory gates, and partner-led lead economics make a 10x outcome unlikely.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion beyond CASGEVY. If patient-starts do not translate into durable economics and 2026-2027 readouts fail to validate a second owned franchise, the market can keep valuing CRSP as cash plus a partner-mediated approved asset rather than a broad platform.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.46
They control validated gene-editing know-how, regulatory trust, and some manufacturing, so AI can help them move faster without replacing the hard parts. The risk is that approvals, treatment logistics, and partner control slow value capture enough for easier therapies or better-funded rivals to win.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$83.74
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case